As type 2 diabetes management evolves, endocrinologist Dr. M.V. Rama Mohan emphasizes that manufacturing and scientific quality are crucial for complex GLP-1 receptor agonists.
More than 100 million adults currently live with diabetes in India, a figure projected to exceed 150 million by 2050.
Strict quality standards and robust clinical evidence ensure consistent performance, stability, and safety for patients requiring long-term chronic care.